Alnylam news. 24, 2023-- Alnylam Pharmaceuticals, Inc. , February 15, 2024--Alnylam Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. (ALNY) stock. But that’s exactly what’s happening at Alnylam. Alnylam’s stock price was around $148 each as of Friday Feb 16, 2024 · February 16, 2024 · 26 min read. From the "Eureka!" moment of discovering RNA interference (RNAi) to the clinical progress and the potential patient impact of the development of RNAi therapeutics, this 15-year journey A high-level overview of Alnylam Pharmaceuticals, Inc. Alnylam is headquartered in Cambridge, MA. Yvonne Greenstreet, at year-end 2021. 86%. Feb 15, 2024 · Alnylam posts Q4 topline miss; pushes back key data readout Feb. John has served as Alnylam's CEO since our founding in 2002. --(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. The 300mg dose achieved greater than 90% TTR reduction on day 15, a 97% reduction on day 29, and a 93% sustained VP, Investor Relations & Corporate Communications investors@alnylam. ALNY | Complete Alnylam Pharmaceuticals Inc. 20, 2023-- Alnylam Pharmaceuticals, Inc. Download PDF. 20. Get the latest Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it has entered into a strategic agreement with Roche to develop and commercialize zilebesiran, Alnylam’s investigational RNAi therapeutic for the treatment of hypertension, which is currently May 24, 2022 · Various statements in this release concerning Alnylam's future expectations, plans and prospects, including, without limitation, Alnylam’s views with respect to the safety and efficacy of lumasiran as demonstrated by the six-month results of the ILLUMINATE-C Phase 3 study and the potential for lumasiran to substantially reduce plasma oxalate Jul 19, 2023 · CAMBRIDGE, Mass. Yvonne is currently Alnylam's President and Chief Operating Officer. Drug development is a perilous process characterized by big risks, large investment (in the order of billions of dollars) and low success rates. , January 02, 2024 -- ( BUSINESS WIRE )-- Alnylam Pharmaceuticals, Inc. Alnylam's first 2 treatments, ONPATTRO Feb 15, 2024 · Alnylam is executing on its “Alnylam P 5 x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. May 17, 2024 · The latest price target for Alnylam Pharmaceuticals ( NASDAQ: ALNY) was reported by HC Wainwright & Co. Apr 27, 2023 · Still, the positive news came with the disclosure of a new issue: a partial clinical hold on the next part of the trial issued by the Food and Drug Administration because of concerns stemming from preclinical studies. − Achieved Fourth Quarter and Full Year 2022 Global Net Product Revenues of $262 Million and $894 Million, Respectively, Representing 35% Annual Growth Compared to 2021 (43% Using Constant Exchange Rate*) – Feb 15, 2024 · On February 15, 2024, Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) released its 8-K filing, detailing a year of substantial growth and strategic advancements. , November 07, 2023--Alnylam Pharmaceuticals, Inc. (ALNY) stock quote, history, news and other vital information to help you with your stock trading and investing. 70% success Jan 7, 2024 · Alnylam Pharmaceuticals, Inc. Apr 30, 2024 · Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies for patients in international markets, and Alnylam Pharmaceuticals, Inc. The analyst says that the company is confident that the recent APOLLO-B Download PDF. Alnylam is a pioneer in a drugmaking method known as RNA interference, and has brought four medicines to market since 2018. 97B. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth quarter and full year 2023 global OUR PIPELINE. A n early-stage Alzheimer’s disease treatment from Alnylam Pharmaceuticals showed promising signs of benefit in a small clinical trial, the company said Oct 28, 2021 · Alnylam Pharmaceuticals. Alnylam has led the translation of RNA interference (RNAi) from Nobel Prize-winning discovery into an entirely new class of medicines, which we believe has the potential to help people all over the world to live longer, healthier, and fuller lives. October 26, 2023 Alnylam Named a Top Science Employer by Science Magazine for the 5th Year in a Row Sep 9, 2019 · 55 patient education events hosted by Alnylam in the U. Links to all outside sites are provided as a reference for our visitors. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming virtual R&D Day event on the Investors section of the Company’s website, www. The company's bottom line came in at Mar 20, 2024 · Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. View Alnylam Pharmaceuticals, Inc ALNY stock quote prices, financial information, real-time forecasts, and company news Alnylam’s approach to corporate responsibility is accepting challenges to improve the health of humanity. 94 +0. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a Oct 9, 2023 · All statements other than historical statements of fact regarding Alnylam’s expectations, beliefs, goals, plans or prospects including, without limitation, expectations regarding Alnylam’s aspiration to become a leading biotech company and the planned achievement of its “Alnylam P 5 x25” strategy, the potential for Alnylam to identify Aug 3, 2022 · Alnylam is currently testing Amvuttra in a Phase 3 study of cardiomyopathy patients. $ Market cap P/E ratio $ Price 1d change 52-week range. 12, 2022-- Alnylam Pharmaceuticals, Inc. Common Stock (ALNY) news with the latest updates, breaking headlines, news articles, and more from around the web at Oct 6, 2023 · CAMBRIDGE, Mass. The Companyâ s lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). , November 02, 2023--Alnylam Pharmaceuticals, Inc. com 617-551-8276 MEDIA KIT Essential assets and documents related to Alnylam May 14, 2024 · 4,693. 87. (ALNY) stock price, news, historical charts, analyst ratings and financial information from WSJ. patients receiving AMVUTTRA. is a clinical-stage company. ALNY Competitors. Addressing health inequities and removing barriers to medicines and health care is a core Contact: investors@alnylam. Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity. Feb 23, 2023. Visit Site ›. and Europe since launch 6 European countries where patients have broad access to ONPATTRO, if prescribed >370 million patients live in geographies – including Canada, Japan, and in Latin American – where Alnylam is actively working to make ONPATTRO commercially available Feb 8, 2024 · Ijem covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Alnylam Pharma, and Regulus. --(BUSINESS WIRE)--Nov. (NASDAQ: ALNY) Q4 2023 Earnings Call Transcript February 15, 2024. The Investor Relations website contains information about Alnylam Pharmaceuticals, Inc. March 17, 2021. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced its first-place ranking in Boston Globe’s 2023 Top Places to Work in Feb 16, 2024 · The news sent Alnylam’s stock down about 10% since Wednesday's close, resulting in a loss of nearly $2 billion in market capitalization. Filter by Year. Proceed to Site Mar 13, 2024 · CAMBRIDGE, Mass. Sep 13, 2023 · Sept 13 (Reuters) - An outside panel of experts to the U. 15, 2024 9:12 AM ET Alnylam Pharmaceuticals, Inc. The work to explore and identify long-term partners in refugee assistance began more than a year ago when we formalized our Sep 20, 2022 · ALNY. RBC Capital Markets raised the price target on Alnylam Pharmaceuticals Inc (NASDAQ: ALNY ) from $225 to $250. 72%. S. Alnylam has led the translation of RNAi (RNA interference) into an innovative new class of medicines which silence the genes that cause disease or that contribute to disease. At Alnylam, we’re closely monitoring developments and guidance from governments and health Jan 12, 2024 · Alnylam (NASDAQ:ALNY) has been one of the most talked about companies in the ATTR field in recent years due to its novel RNAi (RNA interference) approach. Apr 26, 2023 · All statements other than historical statements of fact regarding Alnylam’s expectations, beliefs, goals, plans or prospects including, without limitation, expectations regarding Alnylam’s aspiration to become a leading biotech company and the planned achievement of its “Alnylam P5x25” strategy, the potential for Alnylam to identify new Apr 26, 2023 · Kristoffer Tripplaar/Sipa USA/AP. com. Feb 15, 2024 · Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity. beats earnings expectations Feb 16, 2024 · NVS. stock news by MarketWatch. Oct 27, 2022 · Alnylam Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity. Jun 14, 2022 · Last year, Alnylam reported sales for Onpattro of $475 million from use in around 2,000 patients, and the drug seems to be well ahead of its rival in the market. D. − Achieved Third Quarter 2022 Global Net Product Revenues of $232 Million for ONPATTRO ®, AMVUTTRA ®, GIVLAARI ®, and OXLUMO ® – It’s not every day that a groundbreaking scientific discovery leads to a potential new class of medicines. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the Apr 25, 2022 · The stakes are high. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful Jan 9, 2022 · Alnylam is executing on its “Alnylam P 5 x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Apr 8, 2019 · Alnylam Conference Call Information. The company, a leader in RNA interference Alnylam has led the translation of RNA interference (RNAi) from Nobel Prize-winning discovery into an entirely new class of medicines, which we believe has the potential to help people all over the world to live longer, healthier, and fuller lives. Sep 13, 2023 · CAMBRIDGE, Mass. $2. We are dedicated to the partnership aspect of this program – our employees, both as experts in their Jan 2, 2024 · CAMBRIDGE, Mass. +33. (“Alnylam”) (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has commenced a private offering of $900 million aggregate principal amount of convertible senior notes due 2027 (the “notes May 15, 2019 · PRESS RELEASE. Alnylam Pharmaceuticals ALNY reported a loss of $1. 2 days ago · Alnylam Pharmaceuticals, Inc. View the latest Alnylam Pharmaceuticals Inc. A webcast presentation will also be available on the Investors page of the Company’s website, www. 00 expecting ALNY to Nov 30, 2023 · – Recognition Marks Alnylam’s Ninth Year in a Row on this Prestigious List, and the Third Consecutive Year Ranking #1 – CAMBRIDGE, Mass. 5% and a 56. --(BUSINESS WIRE)--Jul. July 23, 2019. Results are expected in 2024, according to a federal clinical trials database. The analyst firm set a price target for 400. prescribed AMVUTTRA and their families to receive help accessing this new therapy. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting a virtual R&D Day today. after the Food and Drug Dec 13, 2023 · CAMBRIDGE, Mass. In an interview earlier this year, Stifel analyst Paul Matteis said it would be “plausible” for the drug to bring in $3 billion to $5 billion annually if it succeeds. Through pioneering science, unwavering commitment to patients, and our approved therapies and Nov 2, 2023 · CAMBRIDGE, Mass. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter Jan 7, 2024 · CAMBRIDGE, Mass. PRESS RELEASE. 2 days ago · Arrowhead Pharmaceuticals Corp. , the leading RNAi therapeutics company, today announced its preliminary* fourth quarter and full year 2023 global net product revenues for ONPATTRO, AMVUTTRA Jun 20, 2022 · Our donation of £100,000 (~USD 120,000) per year for the next three years will support the expansion of the charity’s innovative program ‘Pathways to Work,’ which helps refugees become employment-ready in the UK. (Nasdaq Sep 13, 2023 · The group of independent experts voted 9-3 that the benefits of Alnylam’s drug, called patisiran, outweighed its risks for patients with ATTR-CM, a progressive disease that leads to fatal heart May 2, 2024 · CAMBRIDGE, Mass. , to Dr. 's business for stockholders, potential investors, and financial analysts. , May 02, 2024--Alnylam Pharmaceuticals, Inc. March 30, 2020. According to TipRanks , Ijem has an average return of 20. Our pioneering work has delivered the world’s first and only approved RNAi therapeutics Sep 27, 2022 · November 30, 2023 Alnylam Named #1 Largest Employer in MA for 3rd Year in a Row by The Boston Globe Alnylam has been named the #1 Largest Employer in MA for the 3rd year in a row and a Top Place to Work for the 9th year in a row. , July 19, 2023--Alnylam Pharmaceuticals, Inc. The COVID-19 pandemic is having a significant impact on people and communities all over the world and will continue to do so for an indefinite period. Apr 20, 2023. , October 06, 2023--Alnylam Pharmaceuticals, Inc. Sobi made around $42 million from Jun 13, 2022 · Alnylam offers a patient support services program, Alnylam Assist ™, for people in the U. Feb 15, 2024 · CAMBRIDGE, Mass. Read More ›. O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments Aug 3, 2022 · Alnylam is currently testing Amvuttra in a Phase 3 study of cardiomyopathy patients. 30, 2023-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter press releases. alnylam. -3. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced its first-place ranking in Boston Globe’s 2023 Top Places to Work in Jun 8, 2022 · The UK medicines regulator has awarded Alnylam's RNAi-based therapy zilebesiran for hypertension an 'innovation passport', a designation designed to speed up NHS access to promising new medicines. Jul 24, 2023 · CAMBRIDGE, Mass. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Our pioneering science and pipeline of investigational RNAi therapeutics are focused on addressing the needs of patients who have limited or inadequate Dec 14, 2023 · There are now five approved RNAi therapeutics that were discovered at Alnylam, and by the end of 2025, we plan to file Investigational New Drug (IND) applications for at least nine new Alnylam-led RNAi programs, including five for targets expressed in the liver, two for the central nervous system (CNS), and one each for adipose tissue and muscle. Sep 12, 2022. Find information about Alnylam's pharmaceutical products: ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), and AMVUTTRA® (vutrisiran). -- (BUSINESS WIRE)--Dec. During the event, the Company plans to Mar 2, 2023 · In September of last year, Alnylam was named the #1 Best Workplace for Innovators by Fast Company (our second year in a row on the list) and we're thrilled to share that Fast Company has recognized us once again, this time as one of the Most Innovative Companies for 2023, and #5 in the Medicines and Therapeutics category. , September 13, 2023--Alnylam Pharmaceuticals, Inc. October 26, 2023 Alnylam Named a Top Science Employer by Science Magazine for the 5th Year in a Row Founded in 2002 by a team of distinguished life sciences leaders, Alnylam’s vision is to harness the potential of RNAi therapeutics to transform the lives of people living with diseases for which there are limited or inadequate treatment options. Date. on Tuesday, May 7, 2024. CAMBRIDGE, Mass. May 02, 2024. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. But none are blockbusters, and Alnylam still isn’t profitable. Jul 27, 2022 - Publication in Nature Communications Reports that People with Loss of Function Mutations in the INHBE Gene Have Reduced Abdominal Fat, a Favorable Metabolic Profile, and are at Lower Risk of Cardiovascular Disease and Type 2 Diabetes - Mar 30, 2020 · Alnylam's Response to COVID-19. Dec 18, 2023 · Alnylam reported impressive phase 1 results of ALN-TTRsc04 in healthy volunteers. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that results from its Phase 1 study of zilebesiran, an Mar 10, 2023 · Harnessing Human Genetics to Power the Next Wave of RNAi Therapeutics. , March 13, 2024--Alnylam Pharmaceuticals, Inc. com, on December 15, 2022 at 8:30 am ET. Alnylam Pharmaceuticals. Feb 15, 2024. Title. Oct 13, 2021 · Alnylam is contributing $1 million to support Acumen America in its efforts to impact 75 million people in the U. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new results from an interim analysis of exploratory data from View the latest Alnylam Pharmaceuticals Inc. Alnylam and Regeneron said they will share the new results from human studies with the agency to lift the hold. Dec 8, 2022 · Dec 08, 2022. The harsh reality is that most investigational drugs (80-90%) do not result in approved Oct 9, 2023 · Alnylam is executing on its “Alnylam P 5 x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation Feb 23, 2023 · Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Period Activity. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present new results for patisiran, an May 20, 2023 · CAMBRIDGE, Mass. 8, 2022-- Alnylam Pharmaceuticals, Inc. , May 20, 2023--Alnylam Pharmaceuticals, Inc. The company recorded a net loss of nearly $853 million last year. Jul 27, 2022 · Alnylam Uncovers Genetic Mutations in INHBE That Protect Against Abdominal Obesity. O) said on Monday it would not pursue expanded use of its drug to treat a potentially fatal heart disease in the U. Alnylam launches the first ever RNAi therapeutic approved in Canada. 10 per share in the fourth quarter of 2023, narrower than the Zacks Consensus Estimate of a loss of $1. This guides our ongoing work tackling unprecedented and complex challenges, taking courageous action, and using our business as a force for good. Apr 18, 2024. We are not just writing a check to tick a box. The company had incurred a loss Nov 7, 2023 · CAMBRIDGE, Mass. 6 days ago · Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results. Today we announced the planned Chief Executive Officer transition of John Maraganore, Ph. Apr 25, 2022 · The market opportunity, along with an improved understanding of how to combat the disease, has made TTR cardiomyopathy a research focus for drug companies. The following content may not be associated with Alnylam Pharmaceuticals. Oct 27, 2022. --(BUSINESS WIRE)--Sep. Alnylam Issues 2023 Corporate Responsibility Report. , December 13, 2023--Alnylam Pharmaceuticals, Inc. View real-time stock prices and stock quotes for a full financial overview. financial markets open. Personalized support program for. − Achieved Fourth Quarter and Full Year 2023 Global Net Product Revenues of $346 Million and $1,241 Million, Respectively, Representing 39% Annual Growth Compared to 2022 – Mar 5, 2024 · Alnylam is executing on its “Alnylam P 5 x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam Management will discuss this collaboration via conference call on Monday, April 8, 2019 at 8:30 am ET. Oct 1, 2022 · Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. (ALNY) Stock PFE , BBIO By: Dulan Lokuwithana , SA News Editor 4 Comments mohd izzuan . by 2024. Alnylam is executing on its “Alnylam P 5 x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional About Alnylam Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to improve the lives of people afflicted with rare genetic, cardio-metabolic, and hepatic infectious diseases. March 10, 2023. Over the past few years, Intellia Therapeutics, Novo Nordisk and AstraZeneca have developed or acquired prospective treatments for the disease, joining Ionis Pharmaceuticals and Alnylam. Food and Drug Administration on Wednesday backed the expanded use of Alnylam Pharmaceuticals' (ALNY. Alnylam Wins Prestigious Prix Galien Canada Award for Best Innovative Product with First-Ever Health Canada-Approved RNAi Therapeutic, ONPATTRO® (patisiran) Download PDF ›. Find our upcoming events and listen to webcasts from past events. Jan 9, 2022 · Alnylam is executing on its “Alnylam P 5 x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation Feb 10, 2022 · Alnylam is executing on its “Alnylam P 5 x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation Aug 18, 2022 · Various statements in this release concerning Alnylam's future expectations, plans and prospects, including, without limitation, Alnylam’s views with respect to the safety and efficacy of patisiran for the treatment of ATTR amyloidosis with cardiomyopathy, the planned presentation of full data from the APOLLO-B study as well as from other Oct 10, 2023 · Oct 9 (Reuters) - Alnylam Pharmaceuticals (ALNY. Feb 15, 2024 · (RTTNews) - Alnylam Pharmaceuticals Inc. May 07, 2024. (ALNY) revealed Loss for fourth quarter that decreased from the same period last year and beat the Street estimates. --(BUSINESS WIRE)--Apr. Download PDF ›. Alnylam Assist includes Case Managers, a team dedicated to helping assist patients with verification of insurance benefits and financial assistance for those who qualify. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended Mar 31, 2023 · Alnylam to Webcast Conference Call Discussing First Quarter 2023 Financial Results. Stay up-to-date on Alnylam Pharmaceuticals, Inc. Alnylam Challengers is a multi-dimensional commitment for Alnylam. O) gene silencing drug to treat a Oct 25, 2023 · All statements other than historical statements of fact regarding Alnylam’s expectations, beliefs, goals, plans or prospects including, without limitation, expectations regarding Alnylam’s aspiration to become a leading biotech company and the planned achievement of its “Alnylam P 5 x25” strategy, the potential for Alnylam to identify Sep 12, 2022 · Alnylam Announces Proposed Offering of $900 Million Convertible Senior Notes. To access the call, please dial 800-289-0438 (domestic) or 323-794-2423 Jul 11, 2023 · November 30, 2023 Alnylam Named #1 Largest Employer in MA for 3rd Year in a Row by The Boston Globe Alnylam has been named the #1 Largest Employer in MA for the 3rd year in a row and a Top Place to Work for the 9th year in a row. Updated July 17, 2020. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2023 on Thursday, May 4, 2023, before the U. (ALNY) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. He will support the leadership transition in a Mar 6, 2024 · Data from a mid-stage study shows that Alnylam (ALNY) and Roche-partnered zilebesiran, when added to standard-of-care, lowers blood pressure significantly in adults with mild-to-moderate hypertension. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that NASDAQ has halted trading of the Company’s common 4 days ago · Get Alnylam Pharmaceuticals Inc (ALNY. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the launch of the Family Health History Road Trip, its Nov 30, 2023 · – Recognition Marks Alnylam’s Ninth Year in a Row on this Prestigious List, and the Third Consecutive Year Ranking #1 – CAMBRIDGE, Mass. Through pioneering science, unwavering commitment to patients, and our approved therapies and Find the latest Alnylam Pharmaceuticals, Inc. vd dh ai me it ni vy sb qf uq